SCHEMBL12115652

SCHEMBL12115652

Cc1nc(-c2ccc3c(N(CC(=O)OC(C)(C)C)S(=O)(=O)c4cc(Cl)cc(Cl)c4)cccc3c2)no1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.35
GPR119 Q8TDV5 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 6/20 0.34
TP53 P04637 3/20 0.34
MAPK1 P28482 4/20 0.34
TSHR P16473 3/20 0.34
BRD4 O60885 1/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 3/20 0.33
MMP12 P39900 1/20 0.33
BDKRB1 P46663 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1110409 0.88 KEAP1 (0.42) HPGDL3MBTL1LMNATP53MAPK1
SCHEMBL12116122 0.88 KEAP1 (0.37) HPGDBRD4HTTBDKRB1KEAP1
SCHEMBL12116064 0.86 MAPT (0.38) HPGDGPR119LMNATP53MAPK1
SCHEMBL12116075 0.85 GPR119 (0.36) GPR119L3MBTL1LMNATP53MAPK1
SCHEMBL12116089 0.85 HCRTR2 (0.35) HPGDTP53TSHRBRD4MAPT
SCHEMBL1754067 0.82 L3MBTL1 (0.37) L3MBTL1LMNATP53MAPK1TSHR
SCHEMBL12115531 0.81 KEAP1 (0.44) KEAP1NFE2L2PKMMCOLN3
SCHEMBL12115645 0.80 KEAP1 (0.48) MAPTKEAP1NFE2L2PKMMCOLN3
SCHEMBL2055370 0.80 L3MBTL1 (0.35) L3MBTL1LMNATP53MAPK1TSHR
SCHEMBL12116144 0.80 NR1D1 (0.35) HPGDTP53BRD4MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
WO-2009127723-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 HPGD 1273/4885GPR119 12/4885L3MBTL1 3888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.